Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths

Prostate cancer is among the most common cancers in men, and the role of population screening has remained controversial because of overdiagnosis and overtreatment. Health systems have sought clearer, long-term evidence to quantify mortality benefit from blood test–based strategies. New analyses from large randomized cohorts with extended follow-up now help define this balance, showing that prostate-specific antigen (PSA) testing modestly reduces prostate cancer deaths while increasing detection, mainly of earlier-stage disease.

Investigators evaluated screening with the PSA blood test in an updated synthesis published in the Cochrane Database of Systematic Reviews. The analysis revises earlier conclusions that lacked sufficient evidence for a mortality effect and incorporates substantially longer follow-up. The work focuses on population-based screening programs conducted in Europe and North America.

Image: An updated review finds that prostate cancer blood tests likely reduce the risk of death, revising earlier findings that evidence was insufficient (photo courtesy of iStock)

The review identifies PSA-based screening as the core modality and describes emerging strategies intended to sharpen specificity and reduce unnecessary biopsies. These approaches combine PSA testing with a kallikrein panel blood test and magnetic resonance imaging (MRI). The authors also note the use of MRI and active surveillance to identify indolent cancers that may not require aggressive treatment, aiming to limit overtreatment-related harms.

Across six randomized trials totaling nearly 800,000 participants, screening with PSA reduced deaths from prostate cancer by about two per 1,000 men screened. Approximately 500 men would need to be invited to screening to prevent one prostate cancer death, based on a major trial that followed 162,241 men for 23 years. However, screening detected roughly 30% more cancers overall and led to about 36 additional diagnoses per 1,000 men screened, predominantly at earlier stages.

Quality-of-life outcomes—including complications of biopsy, sexual dysfunction, and urinary problems—were not systematically assessed in the included trials. The authors point to external evidence (such as the ProtecT trial) addressing treatment-related harms that decision-makers should consider. The current findings suggest the modest mortality benefit is now observable primarily because trials have matured with extended follow-up, while newer multimodal screening strategies may detect more cancers but remain too early to judge for mortality or harm reduction. 

"With new data now available, we can now say with moderate certainty that PSA screening reduces prostate cancer deaths in men with a sufficient life expectancy," said Dr. Philipp Dahm, senior author from University of Minnesota.

"We want to be clear that this is not a blanket endorsement of universal screening. The decision should always be made between a patient and their doctor, with a full understanding of both the potential benefits and the very real risks of overdiagnosis and unnecessary treatment," said Dr. Juan Franco, first author from Heinrich Heine University Düsseldorf.

Related Links
Cochrane